1046124-81-5 Usage
Description
(6S)-N-(2-amino-4,5,6,7-tetrahydrobenzothiazole-6-yl)-2-nitro-N-propylbenzenesulfonamide is a complex sulfonamide derivative featuring a benzothiazole moiety, a nitro group, and a propylbenzenesulfonamide group. As a chiral molecule with the (6S) configuration, it belongs to a class of compounds known for their antimicrobial and diuretic properties, typically utilized as antibiotics.
Uses
Used in Pharmaceutical Industry:
(6S)-N-(2-amino-4,5,6,7-tetrahydrobenzothiazole-6-yl)-2-nitro-N-propylbenzenesulfonamide is used as a potential antibiotic agent due to its sulfonamide nature, which is known for its antimicrobial properties. The specific application and effectiveness would require further research and clinical trials to determine its suitability and efficacy in treating bacterial infections.
Used in Chemical Research:
In the field of chemical research, (6S)-N-(2-amino-4,5,6,7-tetrahydrobenzothiazole-6-yl)-2-nitro-N-propylbenzenesulfonamide serves as a subject for studying the effects of its unique molecular structure, including the benzothiazole moiety and the nitro group, on its chemical behavior and potential interactions with biological systems.
Check Digit Verification of cas no
The CAS Registry Mumber 1046124-81-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,4,6,1,2 and 4 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1046124-81:
(9*1)+(8*0)+(7*4)+(6*6)+(5*1)+(4*2)+(3*4)+(2*8)+(1*1)=115
115 % 10 = 5
So 1046124-81-5 is a valid CAS Registry Number.
1046124-81-5Relevant articles and documents
A novel scalable synthesis of pramipexole
Zivec, Matej,Anzic, Borut,Gobec, Stanislav
, p. 1125 - 1129 (2011/04/12)
Pramipexole is a dopamine D2 subfamily receptor agonist that is used for the treatment of Parkinsons disease. We report here on the successful application of the Fukuyama alkylation protocol to the development of a novel and scalable process for synthesis of pramipexole and its pharmaceutically acceptable salts. The synthesis consists of converting the crucial intermediate (S)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole to (6S)-N-(2-amino-4,5,6,7- tetrahydrobenzothiazole-6-yl)-2-nitrobenzenesulfonamide, which is in turn monoalkylated to (6S)-N-(2-amino-4,5,6,7-tetrahydrobenzothiazole-6-yl)-2-nitro- N-propylbenzenesulfonamide. Deprotection of the latter yields pramipexole base, which is finally converted to a crude pramipexole dihydrochloride monohydrate with a yield of over 50% over four steps. The process allows for the telescoping of the final three steps, has high conversion rates of intermediates, offers ease of purification, and preserves high optical purity throughout all of the stages.
